Cytokinetics

Cytokinetics

Yahoo Finance • 17 days ago

Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy

[Wall Street sign in Lower Manhattan, NYC] georgeclerk Cantor Fitzgerald initiated Lexicon Pharmaceuticals (LXRX [https://seekingalpha.com/symbol/LXRX]) at overweight, saying that it is optimistic on upcoming phase 3 data of the SGLT1/2 i... Full story

Yahoo Finance • 23 days ago

Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for "Global Equity Strategy". The letter can be downloaded here. Global markets delivered strong gains during the quarter, suppo... Full story

Yahoo Finance • 28 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 sh... Full story

Yahoo Finance • last month

Top Stock Reports for Meta Platforms, Marvell & Amphenol

Friday, September 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Marvell Technolog... Full story

Yahoo Finance • last month

Cytokinetics to Participate in September Investor Conferences

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor co... Full story

Yahoo Finance • last month

Small-cap bears were back. Was IWM the warning sign?

[A stack of coins is shown on a blue background with a world map] IURII KRASILNIKOV The put-call ratio for the iShares Russell 2000 ETF (IWM [https://seekingalpha.com/symbol/IWM]) surged to 3.58, with Barchart saying the reading marked th... Full story

Yahoo Finance • last month

Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM

Cytokinetics (NasdaqGS: CYTK) reports positive Phase 3 results for aficamten (MYQORZO) in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. The trial is described as the first successful clinical study in this indicati... Full story

Yahoo Finance • 2 months ago

Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop

Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. Continue Reading... Full story

Yahoo Finance • 2 months ago

Cytokinetics posts full data from late-stage trial for lead drug in non-obstructive HCM

[Cytokinetics headquarters in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Cytokinetics (CYTK [https://seekingalpha.com/symbol/CYTK]) traded lower on Friday after releasing full data from a late-stage trial designe... Full story

Yahoo Finance • 2 months ago

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Robert I. Blum, President & CEO of Cytokinetics (NASDAQ:CYTK), reported the sale of 7,500 shares on Aug. 10, 2026, as disclosed in a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $575,700 Shares sold (direc... Full story

Yahoo Finance • 3 months ago

Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight

The congestive heart failure market is expected to witness steady growth over the coming years, driven by the rising prevalence of cardiovascular diseases, an aging global population, and increasing awareness of early diagnosis and disease... Full story

Yahoo Finance • 3 months ago

iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?

Investors choosing between iShares Morningstar Small Cap Value ETF (NYSEMKT:ISCV) and iShares Russell 2000 Value ETF (NYSEMKT:IWN) must weigh the former's significantly lower expense ratio against the latter's massive liquidity and higher... Full story

Yahoo Finance • 3 months ago

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results from La... Full story

Yahoo Finance • 3 months ago

Which Is the Better Long-Term Buy: iShares' Small-Cap IWM or Invesco's Tech-Heavy QQQ?

Key Points iShares Russell 2000 ETF targets small-cap growth and value stocks, while Invesco QQQ Trust, Series 1 focuses on the largest non-financial leaders on the Nasdaq. Invesco QQQ Trust, Series 1 carries a slightly lower expense rati... Full story

Yahoo Finance • 3 months ago

Citi's picks and pans for H2 '26: REITs, tech, consumer, health

[Citibank headquarters in Canary Wharf, London, UK] VV Shots Citi released its roadmap for the second half of 2026, including a macro-to-micro view of equity sectors. "Our recently revised S&P 500 (SPY [https://seekingalpha.com/symbol/SP... Full story

Yahoo Finance • 3 months ago

Which iShares Value ETF Is Better, the Small Cap-Focused IWN or IJJ Targeting Mid-Cap Stocks?

While the iShares S&P Mid-Cap 400 Value ETF (NYSEMKT:IJJ) focuses on mid-sized companies, the iShares Russell 2000 Value ETF (NYSEMKT:IWN) offers exposure to small-cap value stocks with a broader portfolio and slightly higher costs. Both... Full story

Yahoo Finance • 4 months ago

Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?

Is CYTK a good stock to buy? We came across a bullish thesis on Cytokinetics, Incorporated on TradersPro's Substack. In this article, we will summarize the bulls' thesis on CYTK. Cytokinetics, Incorporated's share was trading at $78.78 as... Full story

Yahoo Finance • 4 months ago

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Quick Read Crinetics Pharmaceuticals leads as the cleanest buyout candidate at $3.79 billion; Cytokinetics' FDA-approved Myqorzo attracts Bristol Myers Squibb or Novartis but costs $10.86 billion. ARWR's ARO-INHBE nearly doubled tirzepati... Full story

Yahoo Finance • 4 months ago

Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment

Cytokinetics (NASDAQ:CYTK) is one of the most promising mid-cap stocks to buy according to analysts. On June 1, Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic... Full story

Yahoo Finance • 4 months ago

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (a... Full story